Matches in SemOpenAlex for { <https://semopenalex.org/work/W3138609338> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W3138609338 endingPage "S201" @default.
- W3138609338 startingPage "S201" @default.
- W3138609338 abstract "G-CSF are recommended to prevent febrile neutropenia (FN) in high risk (FN>20%) chemotherapy treatments. When the FN risk is 10-20%, assessment of patient and disease characteristics is necessary. Exploring physicians’ preferences on their use of G-CSF would help to understand what determines their choices. We use a Discrete Choice Experiment (DCE) method, in a national sample of oncologists to elicit their preferences in term of G-CSF use. The most relevant attributes and their levels were determined with a multidisciplinary expert committee and comprised injection site pain, bone pain, Influenza-like illness (ILI), fever, residual risk of FN with G-CSF, biosimilar use, injections number and cost per cycle. Eight scenarios were completed per participant for primary and secondary prophylaxis. A mixed-effect logit model estimated the preferences. Two hundred and five participants: male, 61%, with ≤10- (40.5%), 11-20 (36.1%), ≥21 (23.4%) years of experience in oncology and private (18%), public (73.2%) or mixed (8.8%) exercise. In primary prophylaxis, significant criteria mainly focused on the injection number per cycle (coef. 0.212, p<10-4) and the total cost per cycle (coef. 0.1139, p<10-4), before the safety profile (pain at the injection site as most avoided tolerance criterion, (coef. 0.0768, p<10-4)) and the efficacy (coef. 0.039, p=0.0152). The biosimilar profile is well-received (coef. 0.1446 p<10-4). In secondary prophylaxis, efficacy became a more significant criterion of preference in addition to other criteria (coef. 0.0939, p<10-4).Tabled 1AttributesPrimary prophylaxisSecondary prophylaxisCoefficientp valueCoefficientp valueRisk of febrile neutropenia0.0390.01520.0939<10-4Biosimilar0.1446<10-40.1102<10-4Cost/ cycle (€)0.1139<10-40.1056<10-4Injection number0.212<10-40.1368<10-4Injection site pain0.0768<10-40.04630.0054Bone pain-0.04020.0123-0.072<10-4Influenza-like illness (ILI)/ fever-0.03660.0228-0.05120.0021Log-Likelihood-2130.81-2246.5Participant number205205 Open table in a new tab In primary prophylaxis, physicians’ preferences for G-CSF are based on patients’ comfort and costs more than efficacy which comes into play in secondary prophylaxis. Use of a biosimilar is well accepted in both settings." @default.
- W3138609338 created "2021-03-29" @default.
- W3138609338 creator A5035949813 @default.
- W3138609338 creator A5046201070 @default.
- W3138609338 creator A5054085885 @default.
- W3138609338 creator A5055798090 @default.
- W3138609338 creator A5069743559 @default.
- W3138609338 creator A5072668656 @default.
- W3138609338 date "2021-03-01" @default.
- W3138609338 modified "2023-10-06" @default.
- W3138609338 title "FP06.01 Discrete Choice Experiment to Estimate Physicians’ Preferences in Terms of G-CSF use for Febrile Neutropenia Primary and Secondary Prophylaxis" @default.
- W3138609338 doi "https://doi.org/10.1016/j.jtho.2021.01.097" @default.
- W3138609338 hasPublicationYear "2021" @default.
- W3138609338 type Work @default.
- W3138609338 sameAs 3138609338 @default.
- W3138609338 citedByCount "0" @default.
- W3138609338 crossrefType "journal-article" @default.
- W3138609338 hasAuthorship W3138609338A5035949813 @default.
- W3138609338 hasAuthorship W3138609338A5046201070 @default.
- W3138609338 hasAuthorship W3138609338A5054085885 @default.
- W3138609338 hasAuthorship W3138609338A5055798090 @default.
- W3138609338 hasAuthorship W3138609338A5069743559 @default.
- W3138609338 hasAuthorship W3138609338A5072668656 @default.
- W3138609338 hasBestOaLocation W31386093381 @default.
- W3138609338 hasConcept C120195587 @default.
- W3138609338 hasConcept C126322002 @default.
- W3138609338 hasConcept C151956035 @default.
- W3138609338 hasConcept C194828623 @default.
- W3138609338 hasConcept C2776694085 @default.
- W3138609338 hasConcept C2777063308 @default.
- W3138609338 hasConcept C2778850193 @default.
- W3138609338 hasConcept C44249647 @default.
- W3138609338 hasConcept C59491497 @default.
- W3138609338 hasConcept C71924100 @default.
- W3138609338 hasConcept C95057490 @default.
- W3138609338 hasConceptScore W3138609338C120195587 @default.
- W3138609338 hasConceptScore W3138609338C126322002 @default.
- W3138609338 hasConceptScore W3138609338C151956035 @default.
- W3138609338 hasConceptScore W3138609338C194828623 @default.
- W3138609338 hasConceptScore W3138609338C2776694085 @default.
- W3138609338 hasConceptScore W3138609338C2777063308 @default.
- W3138609338 hasConceptScore W3138609338C2778850193 @default.
- W3138609338 hasConceptScore W3138609338C44249647 @default.
- W3138609338 hasConceptScore W3138609338C59491497 @default.
- W3138609338 hasConceptScore W3138609338C71924100 @default.
- W3138609338 hasConceptScore W3138609338C95057490 @default.
- W3138609338 hasIssue "3" @default.
- W3138609338 hasLocation W31386093381 @default.
- W3138609338 hasOpenAccess W3138609338 @default.
- W3138609338 hasPrimaryLocation W31386093381 @default.
- W3138609338 hasRelatedWork W2117609882 @default.
- W3138609338 hasRelatedWork W2398255791 @default.
- W3138609338 hasRelatedWork W2479932493 @default.
- W3138609338 hasRelatedWork W2583990994 @default.
- W3138609338 hasRelatedWork W2732187261 @default.
- W3138609338 hasRelatedWork W2769130234 @default.
- W3138609338 hasRelatedWork W2905956412 @default.
- W3138609338 hasRelatedWork W2919797952 @default.
- W3138609338 hasRelatedWork W2998770471 @default.
- W3138609338 hasRelatedWork W3010100147 @default.
- W3138609338 hasVolume "16" @default.
- W3138609338 isParatext "false" @default.
- W3138609338 isRetracted "false" @default.
- W3138609338 magId "3138609338" @default.
- W3138609338 workType "article" @default.